Literature DB >> 18829575

Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer.

Willie Wilson1, Albert S Baldwin.   

Abstract

Constitutive nuclear factor kappaB (NF-kappaB) activation is among the many deregulated signaling pathways that are proposed to drive pancreatic cancer cell growth and survival. Recent reports suggest that glycogen synthase kinase-3beta (GSK-3beta) plays a key role in maintaining basal NF-kappaB target gene expression and cell survival in pancreatic cancer cell lines. However, the mechanism by which GSK-3beta facilitates constitutive NF-kappaB signaling in pancreatic cancer remains unclear. In this report, we analyze the contributions of both GSK-3 isoforms (GSK-3alpha and GSK-3beta) in regulating NF-kappaB activation and cell proliferation in pancreatic cancer cell lines (Panc-1 and MiaPaCa-2). We show that GSK-3 isoforms are differentially required to maintain basal NF-kappaB DNA binding activity, transcriptional activity, and cell proliferation in Panc-1 and MiaPaCa-2 cells. Our data also indicate that IkappaB kinase (IKK) subunits are not equally required to regulate pancreatic cancer-associated NF-kappaB activity and cell growth. Importantly, we provide the first evidence that GSK-3 maintains constitutive NF-kappaB signaling in pancreatic cancer by regulating IKK activity. These data provide new insight into GSK-3-dependent NF-kappaB regulation and further establish GSK-3 and IKK as potential therapeutic targets for pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829575      PMCID: PMC2647811          DOI: 10.1158/0008-5472.CAN-08-1061

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

Review 1.  Glycogen synthase kinase-3: properties, functions, and regulation.

Authors:  A Ali; K P Hoeflich; J R Woodgett
Journal:  Chem Rev       Date:  2001-08       Impact factor: 60.622

2.  Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418.

Authors:  Ratan Bhat; Yafeng Xue; Stefan Berg; Sven Hellberg; Mats Ormö; Yvonne Nilsson; Ann-Cathrin Radesäter; Eva Jerning; Per-Olof Markgren; Thomas Borgegård; Martin Nylöf; Alfredo Giménez-Cassina; Félix Hernández; Jose J Lucas; Javier Díaz-Nido; Jesús Avila
Journal:  J Biol Chem       Date:  2003-08-19       Impact factor: 5.157

3.  Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3.

Authors:  C J Fiol; A M Mahrenholz; Y Wang; R W Roeske; P J Roach
Journal:  J Biol Chem       Date:  1987-10-15       Impact factor: 5.157

4.  Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase.

Authors:  S E Ross; R L Erickson; N Hemati; O A MacDougald
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

5.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation.

Authors:  K P Hoeflich; J Luo; E A Rubie; M S Tsao; O Jin; J R Woodgett
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

Review 6.  Nuclear factor-kappaB: the enemy within.

Authors:  Bharat B Aggarwal
Journal:  Cancer Cell       Date:  2004-09       Impact factor: 31.743

7.  Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer.

Authors:  Susanne Liptay; Christoph K Weber; Leopold Ludwig; Martin Wagner; Guido Adler; Roland M Schmid
Journal:  Int J Cancer       Date:  2003-07-20       Impact factor: 7.396

8.  Transient and selective NF-kappa B p65 serine 536 phosphorylation induced by T cell costimulation is mediated by I kappa B kinase beta and controls the kinetics of p65 nuclear import.

Authors:  Ivan Mattioli; Andrea Sebald; Cyril Bucher; Roch-Philippe Charles; Hiroyasu Nakano; Takahiro Doi; Michael Kracht; M Lienhard Schmitz
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

9.  IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.

Authors:  Elizabeth A Duncan; Christine A Goetz; Sarah J Stein; Katie J Mayo; Brian J Skaggs; Karl Ziegelbauer; Charles L Sawyers; Albert S Baldwin
Journal:  Mol Cancer Ther       Date:  2008-02-01       Impact factor: 6.261

10.  Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes.

Authors:  Robert F Schwabe; David A Brenner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-07       Impact factor: 4.052

View more
  59 in total

Review 1.  NF-κB addiction and its role in cancer: 'one size does not fit all'.

Authors:  M M Chaturvedi; B Sung; V R Yadav; R Kannappan; B B Aggarwal
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

2.  GSK-3 represses growth factor-inducible genes by inhibiting NF-kappaB in quiescent cells.

Authors:  Julie R Graham; John W Tullai; Geoffrey M Cooper
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

3.  Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells.

Authors:  Benoît Marchand; Dominique Arsenault; Alexandre Raymond-Fleury; François-Michel Boisvert; Marie-Josée Boucher
Journal:  J Biol Chem       Date:  2015-01-05       Impact factor: 5.157

Review 4.  Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis.

Authors:  Ami Patel; Harika Sabbineni; Andrea Clarke; Payaningal R Somanath
Journal:  Life Sci       Date:  2016-05-28       Impact factor: 5.037

5.  Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth.

Authors:  Yvette M Carter; Selvi Kunnimalaiyaan; Herbert Chen; T Clark Gamblin; Muthusamy Kunnimalaiyaan
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

Review 6.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

7.  TCF/beta-catenin plays an important role in HCCR-1 oncogene expression.

Authors:  Goang-Won Cho; Mi-Hwa Kim; Seung Hyun Kim; Seon-Ah Ha; Hyun Kee Kim; Sanghee Kim; Jin W Kim
Journal:  BMC Mol Biol       Date:  2009-05-12       Impact factor: 2.946

8.  Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.

Authors:  Shadi Mamaghani; Satish Patel; David W Hedley
Journal:  BMC Cancer       Date:  2009-04-30       Impact factor: 4.430

9.  Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.

Authors:  V Bilim; A Ougolkov; K Yuuki; S Naito; H Kawazoe; A Muto; M Oya; D Billadeau; T Motoyama; Y Tomita
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

10.  Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha.

Authors:  E C Merkhofer; P Cogswell; A S Baldwin
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.